Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8

Human Gene Therapy

Volumn 24, Issue 6, 2013, Pages 584-594

  Pan, Xiufang ^a   Yue, Yongping ^a   Zhang, Keqing ^a   Lostal, William ^a,b   Shin, Jin Hong ^a,c   Duan, Dongsheng ^a  

^a University of Missouri   (United States)

^b GÉNÉTHON   (France)

^c Pusan National University Yangsan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS TYPE 8; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR GENE THERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; EXPERIMENTAL DOG; FEMALE; GENE DOSAGE; HEART MUSCLE; KIDNEY; LIVER; LUNG; LYMPHOCYTIC INFILTRATION; MALE; NEWBORN; NON INVASIVE PROCEDURE; NONHUMAN; PANCREAS; PROMOTER REGION; REPORTER GENE; SAFETY; SEROTYPE; SKELETAL MUSCLE; SPLEEN; T LYMPHOCYTE; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS TYPING;

ANIMALS; ANIMALS, NEWBORN; DEPENDOVIRUS; DOGS; FEMALE; GENOME, VIRAL; HUMANS; INJECTIONS, INTRAVENOUS; JUGULAR VEINS; MALE; MUSCLE, SKELETAL; MYOCARDIUM; SEROTYPING; T-LYMPHOCYTES; TIME FACTORS; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CANIS FAMILIARIS; MAMMALIA; RODENTIA; ROUS SARCOMA VIRUS;

EID: 84879182056     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.044     Document Type: Article

References (32)

1. Bish, L.T., Sleeper, M.M., Brainard, B., et al. (2008). Percutaneous transendocardial delivery of self-complementary adenoassociated virus 6 achieves global cardiac gene transfer in canines. Mol. Ther. 16, 1953-1959.
2. Bostick, B., Ghosh, A., Yue, Y., et al. (2007). Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 14, 1605-1609.
3. Brown, B.D., and Naldini, L. (2009). Exploiting and antagonizing microrna regulation for therapeutic and experimental applications. Nat. Rev. Genet. 10, 578-585.
4. Denard, J., Beley, C., Kotin, R., et al. (2012). Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J. Virol. 86, 6620-6631.
5. Duan, D. (2011a). Duchenne muscular dystrophy gene therapy: lost in translation? Res. Rep. Biol. 2, 31-42.
6. Duan, D. (2011b). Gene delivery to the heart: an updated review on vectors and methods. J. Gene Med. 13, 556.
7. Fine, D.M., Shin, J.H., Yue, Y., et al. (2011). Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul. Disord. 21, 453-461.
8. Gregorevic, P., Blankinship, M.J., Allen, J.M., et al. (2004). Systemic delivery of genes to striated muscles using adenoassociated viral vectors. Nat. Med. 10, 828-834.
9. Inagaki, K., Fuess, S., Storm, T.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53.
10. Ishikawa, K., Tilemann, L., Fish, K., and Hajjar, R.J. (2011). Gene delivery methods in cardiac gene therapy. J. Gene Med. 13, 566-572.
11. Jaski, B.E., Jessup, M.L., Mancini, D.M., et al. (2009). Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (Cupid Trial), a first-in-human phase 1/2 clinical trial. J. Card. Fail. 15, 171-181.
12. Jessup, M., Greenberg, B., Mancini, D., et al. (2011). Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 +-ATPase in patients with advanced heart failure. Circulation 124, 304-313.
13. Katz, M.G., Fargnoli, A.S., Tomasulo, C.E., et al. (2011). Modelspecific selection of molecular targets for heart failure gene therapy. J. Gene Med. 13, 573-586.
14. Kelly, E.J., and Russell, S.J. (2009). MicroRNAs and the regulation of vector tropism. Mol. Ther. 17, 409-416.
15. Koeberl, D.D., Pinto, C., Sun, B., et al. (2008). Aav vectormediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol. Ther. 16, 665-672.
16. Kratlian, R.G., and Hajjar, R.J. (2012). Cardiac gene therapy: from concept to reality. Curr. Heart Fail. Rep. 9, 33-39.
17. Lai, Y., and Duan, D. (2012). Progress in gene therapy of dystrophic heart disease. Gene Ther. 19, 678-685.
18. Li, X., Eastman, E.M., Schwartz, R.J., and Draghia-Akli, R. (1999). Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17, 241-245.
19. Nashef, S.A., Roques, F., Sharples, L.D., et al. (2012). Euroscore II. Eur. J. Cardiothorac. Surg. 41, 734-744; discussion 744-745.
20. Pacak, C.A., Mah, C.S., Thattaliyath, B.D., et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3-9.
21. Rapti, K., Louis-Jeune, V., Kohlbrenner, E., et al. (2012). Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol. Ther. 20, 73-83.
22. Sarkar, R., Mucci, M., Addya, S., et al. (2006). Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum. Gene Ther. 17, 427-439.
23. Shin, J.H., Yue, Y., and Duan, D. (2012a). Recombinant adenoassociated viral vector production and purification. Methods Mol. Biol. 798, 267-284.
24. Shin, J.H., Yue, Y., Smith, B., and Duan, D. (2012b). Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. Hum. Gene Ther. 23, 287-294.
25. Shin, J.H., Yue, Y., Srivastava, A., et al. (2012c). A simplified immune suppression scheme leads to persistent microdystrophin expression in Duchenne muscular dystrophy dogs. Hum. Gene Ther. 23, 202-209.
26. Smith, B.F., Yue, Y., Woods, P.R., et al. (2011). An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab. Invest. 91, 216-231.
27. Wang, Z., Zhu, T., Qiao, C., et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321-328.
28. Wasala, N.B., Shin, J.H., and Duan, D. (2011). The evolution of heart gene delivery vectors. J. Gene Med. 13, 557-565.
29. Yue, Y., Ghosh, A., Long, C., et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther. 16, 1944-1952.
30. Yue, Y., Shin, J.-H., and Duan, D. (2011). Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol. Biol. 709, 313-329.
31. Zhu, X., McTiernan, C.F., Rajagopalan, N., et al. (2012). Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression. Hum. Gene Ther. 23, 722-732.
32. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080.